| __timestamp | Amgen Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4699000000 | 15746000 |
| Thursday, January 1, 2015 | 4846000000 | 13392000 |
| Friday, January 1, 2016 | 5062000000 | 9290000 |
| Sunday, January 1, 2017 | 4870000000 | 7672000 |
| Monday, January 1, 2018 | 5332000000 | 15293000 |
| Tuesday, January 1, 2019 | 5150000000 | 22648000 |
| Wednesday, January 1, 2020 | 5730000000 | 21864000 |
| Friday, January 1, 2021 | 5368000000 | 37318000 |
| Saturday, January 1, 2022 | 5414000000 | 48130000 |
| Sunday, January 1, 2023 | 6179000000 | 108146000 |
| Monday, January 1, 2024 | 7096000000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of industry leaders is crucial. Amgen Inc., a titan in the field, has consistently demonstrated robust financial health. From 2014 to 2023, Amgen's Selling, General, and Administrative (SG&A) expenses have shown a steady increase, peaking at approximately $6.2 billion in 2023. This represents a 31% rise over the decade, reflecting its expansive operational strategies.
Conversely, Madrigal Pharmaceuticals, Inc., a smaller yet ambitious player, has seen its SG&A expenses grow from $15.7 million in 2014 to $108 million in 2023. This staggering 587% increase underscores Madrigal's aggressive growth and investment in its operations.
This comparison highlights the contrasting scales and strategies of these companies, offering insights into their financial commitments and market positioning over the years.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Exelixis, Inc.
Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Amgen Inc. and Agios Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: BeiGene, Ltd. vs Madrigal Pharmaceuticals, Inc.
Bio-Techne Corporation or Madrigal Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Alpine Immune Sciences, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Madrigal Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?